Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.
Novartis sold more medicine than expected this quarter, and their new drug pipeline looks strong, which means they're ready to handle competition from cheaper copycat drugs. When you hear a company beat expectations and has new ideas coming, it's a sign they might stay healthy and growing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.